Scholz-hidden

(l-r) Paul Mizue, President of the Hawaii Prostate Cancer Coalition, Mark Scholz, MD, and Phil Olsen, HPCC Founder

Dr. Mark Scholz, Medical Director of Prostate Oncology Specialists, Marina del Rey, CA was guest speaker at the November 11, 2015 Kuakini US Too support group meeting. He discussed the features of the two new drugs for advanced prostate cancer, abiraterone (Zytiga) and enzalutamide (Xtandi), their appropriate applications for patients, side effects, use in mono-therapy or in combination, and effectiveness in halting prostate cancer progression.

DISCLAIMER: The information and opinions expressed on this web site are not an endorsement or recommendation for any medical treatment, product, service or course of action by the Hawaii Prostate Cancer Coalition and are not intended to be a substitute for professional medical advice, diagnosis or treatment. You should not rely solely upon information found in this web site but instead seek the advice of your physician or other qualified health care provider who is familiar with your individual medical needs.

98-1214 Alolua Street, Aiea, HI 96701 usToo.hawaii@gmail.com 808-222-0425